BRD4 and ovarian carcinoma: HGSOC patients harboring focal amplification of the chromosome 19, in regions that encompass BRD4 (19p13.2) [13, 19, 65], tended to show advanced-stage ovarian cancer (97% of the patients were diagnosed with stage III or IV tumors) [19].